

## AMENDMENTS TO THE CLAIMS

1-6. (Canceled)

7. (Currently Amended) ~~A composition comprising a~~ polypeptide comprising a single interleukin-8 (IL-8) fragment ~~and a pharmaceutically acceptable carrier~~, wherein said IL-8 fragment stimulates the differentiation of fibroblasts to myofibroblasts, and wherein said fragment comprises an ELR motif and an amino acid sequence that is ~~at least 90%~~ identical to an N-terminal amino acid sequence of IL-8, and is no greater than about ~~8~~ 15 amino acids in length, wherein the N-terminal amino acid sequence comprises a subsequence of residues 1-36 of SEQ ID NO.: 5 or residues 1-38 of SEQ ID NO.: 4.

8. (Currently Amended) ~~A composition comprising a~~ polypeptide comprising a single interleukin-8 (IL-8) fragment ~~and a pharmaceutically acceptable carrier~~, wherein the IL-8 fragment comprises an amino acid sequence selected from the group consisting of SEQ ID NO:8 and SEQ ID NO:9, and is no greater than about 15 amino acids in length, wherein the polypeptide is a cyclic polypeptide.

9-87. (Canceled)

88. (Previously Presented) A polypeptide comprising a single interleukin-8 (IL-8) fragment, wherein said IL-8 fragment consists of amino acid sequence SAKELR (SEQ ID NO.: 8).

89. (Canceled)

90. (Previously Presented) A polypeptide comprising a single interleukin-8 (IL-8) fragment, wherein said IL-8 fragment consists of amino acid sequence AVLPRSAKELR (SEQ ID NO.: 9).

91. (Canceled)

92. **(Currently Amended)** A composition comprising the polypeptide of claim 7, 8, 88, 89, or 90 ~~or 91~~ and a pharmaceutically acceptable carrier.

93. **(Currently Amended)** The polypeptide of claim 7, 88, 89, or 90 ~~or 91~~, wherein the polypeptide is a cyclic polypeptide.

94-96. **(Canceled)**

97. **(Currently Amended)** The polypeptide composition of claim 7, wherein the N-terminal amino acid sequence comprises a subsequence of residues 1-36 of SEQ ID NO.: 5.

98. **(Currently Amended)** The polypeptide composition of claim 7, wherein the N-terminal amino acid sequence comprises a subsequence of residues 1-38 of SEQ ID NO.: 4.

99. **(Canceled)**

100. **(Currently Amended)** The polypeptide composition of claim 8, wherein the IL-8 fragment comprises SEQ ID NO: 8.

101. **(Currently Amended)** The polypeptide composition of claim 8, wherein the IL-8 fragment comprises SEQ ID NO: 9.

102. **(New)** The polypeptide of claim 7, wherein the IL-8 fragment is about 5 or more amino acids in length.

103. **(New)** The polypeptide of claim 8, wherein the IL-8 fragment is about 5 or more amino acids in length.